Mukka Proteins Limited Re-appoints Key Directors and Management at 16th AGM
Mukka Proteins Limited re-appointed three Non-Executive Independent Directors and three key management personnel at its 16th AGM on September 10, 2026. The re-appointments for directors and management are for five-year terms, effective January 15, 2027, and January 20, 2027, respectively.
The re-appointment of key leadership positions ensures continuity and stability in the company's operations and strategic direction, which can have a medium-term impact on investor confidence and business execution.
The re-appointment of key directors and management indicates stability and continuity in leadership, which is generally viewed positively by the market.
Mukka Proteins Limited announced that its 16th Annual General Meeting (AGM), held on September 10, 2026, saw the approval of several key re-appointments.
Mr. Karkala Shankar Balachandra Rao, Mr. Hamad Bava, and Mr. Narendra Surendra Kamath were re-appointed as Non-Executive Independent Directors for a second term of five years, commencing January 15, 2027, and concluding on January 14, 2032. These directors are not liable to retire by rotation.
Furthermore, the company re-appointed its key management personnel. Mr. Kalandan Mohammed Haris was re-appointed as Managing Director and Chief Executive Officer for another five-year term, from January 20, 2027, to January 19, 2032. His office is not liable to retire by rotation. Mr. Kalandan Mohammed Althaf was re-appointed as Whole-Time Director and Chief Financial Officer, and Mr. Kalandan Mohammad Arif was re-appointed as Whole-Time Director and Chief Operating Officer. Both will serve for five-year terms, from January 20, 2027, to January 19, 2032. Their offices are subject to retirement by rotation.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.